(Q37427683)

20 August 2017

1 reference

title

The immunotherapy of human cancer with interleukin 2: present status and future directions (English)

1 reference

20 August 2017

0 references

1 reference

Kolitz JE

1

1 reference

20 August 2017

Mertelsmann R

series ordinal

2

1 reference

20 August 2017

publication date

1 January 1991

1 reference

20 August 2017

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

529-542

1 reference

Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Expression of interleukin 2 receptors on activated human B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Long term culture of tumour-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Interleukin 2 high-affinity receptor expression requires two distinct binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Activation of natural killer cells via the p75 interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Activation of peripheral blood T cells via the p75 interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Lymphokine-activated killer cells. Analysis of progenitors and effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Cardiorespiratory effects of immunotherapy with interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Intraperitoneal administration of interleukin-2 in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Appearance of neuropeptides in ascitic fluid after peritoneal therapy with interleukin-2 and lymphokine-activated killer cells for intraabdominal malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Induction of lymphokine-activated killer-like cells by cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

Interleukin-2 augments natural killer cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909109018951

10.3109/07357909109018951

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference